A Phase 3 interventional study of BR1019A and BR1019B in Essential Hypertension and Type 2 Diabetes Mellitus, sponsored by Boryung Pharmaceutical Co., Ltd. Recruiting at 3 sites in 2 countries. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd — 8 open to participants now, 8 under way, 1 of them phase 3. Essential Hypertension · Boryung Pharmaceutical Co., Ltd.
Among the 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd, this one is the 3rd largest by planned enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2024, is one of 11 in phase 3, and was the 30th registered.
481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.
Browse Essential Hypertension studies →8 of the 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+
Boryung Pharmaceutical Co., Ltd
Ages 19+
Boryung Pharmaceutical Co., Ltd
Ages 19+ · Healthy volunteers
Boryung Pharmaceutical Co., Ltd
Ages 19+ · Healthy volunteers
Boryung Pharmaceutical Co., Ltd
Ages 19+ · Healthy volunteers
By country, each count listing its studies:
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 276 is above the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 58 across the 39 interventional studies, 4,542 across the 5 observational. Of the 36 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boryung Pharmaceutical Co., Ltd is the lead sponsor of 143 studies on the registry; 23 are open to participants now.
2 of the studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06220773Phase 3Boryung Pharmaceutical Co., LtdA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | 2026-12 |
| NCT07373613Boryung Pharmaceutical Co., LtdA Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Those who meet the following criteria
Drug: BR1019A · Drug: BR1019B · Drug: BR1019C-1
Drug: BR1019A · Drug: BR1019B-1 · Drug: BR1019C-1
Drug: BR1019B · Drug: BR1019A-1 · Drug: BR1019C-1
Drug: BR1019B · Drug: BR1019C · Drug: BR1019A-1
Subjects take the investigational products once a day for 12 weeks.
Subjects take the investigational products once a day for 12 weeks.
Subjects take the investigational products once a day for 12 weeks.
Subjects take the investigational products once a day for 12 weeks.
Subjects take the investigational products once a day for 12 weeks.
Subjects take the investigational products once a day for 12 weeks.
The change of mean sitting systolic blood pressure from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A-1+BR1019B+BR1019C-1
Time frame: 12 weeks from Baseline Visit
The change of HbA1c from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A+BR1019B-1+BR1019C-1
Time frame: 12 weeks from Baseline Visit
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.
Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's planned 31 months is above that.
Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Apr 2025 → Dec 2026 and completion Apr 2025 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boryung Pharmaceutical Co., Ltd →